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Abstract A monospecific human IgM monoclonal antibody
(mAb), reactive with myosin from human heart, has been
obtained by EBV transformation. This mAb may have a
diagnostic potential in the imaging of myocardial necrosis.
However, owing to the fact that the molecular mass of an IgM is
900 kDa, a poor diffusion and a slow penetration inside necrotic
myocytes could reduce its capacity for scintigraphic detection. In
order to alleviate these problems, we constructed the scFv by
cloning the VH and VL domains into the pHOG21 vector.
Analysis of the V genes proved an unmutated configuration
showing that the immortalized B cell issued from the primary
IgM repertoire. The expression product in Escherichia coli was a
35 kDa scFv fragment with the antigen-binding specificity of the
parental mAb.
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1. Introduction
Human monoclonal antibodies (mAbs) are a new class of
diagnostic and therapeutic agents which have made a substan-
tial impact in the biomedical ¢eld. They are less likely to
provoke the immune response which can severely impair the
clinical e⁄ciency of murine antibodies [1]. Indeed, human
anti-mouse antibodies (HAMA) may accelerate the clearance
of the injected mAb, block its binding to the antigen and/or
trigger allergic reactions. A murine anti-myosin mAb has been
described as a powerful probe for the imaging of myocardial
necrosis [2]. A mAb of entirely human origin may o¡er con-
siderable advantages over the murine antibody.
The EBV transformation of B lymphocytes from a patient
with a bleeding disorder had led to the unexpected immortal-
ization of a B cell secreting a monospeci¢c human anti-myosin
IgM (referred to as B7) [3]. By Western blotting, we previ-
ously showed that B7 recognized the myosin heavy chain of
di¡erent sources (skeletal muscle, cardiac muscle and non-
muscle cells) and of di¡erent species (rabbit, pig, human)
[3]. Using immunohistochemical staining, we also showed
that B7 bound avidly to the myosin of human ventricular
myocardium, but not to that of human aortic smooth muscle
cells [3]. Because of this high avidity for cardiac myosin, B7
may be useful in the imaging of myocardial necrosis after
graft rejection [2], cardiomyopathy [4], suspected myocarditis
[5] and cardiac drug toxicosis [6]. However, because of the
large molecular mass of the IgM (900 kDa), its use in scinti-
graphic detection would appear compromised. The develop-
ment of genetically engineered scFv (around 32 kDa) mole-
cules, which consist of only the antibody variable regions held
together by a £exible linker, was thus considered. ScFv have
the advantage of rapid clearance from the circulation, good
penetration within solid tissue and theoretically, low immuno-
genicity [5].
We constructed the recombinant scFv fragments of B7 into
the expression vector pHOG21 [7]. They were expressed in a
soluble form using Escherichia coli, enriched by immobilized
metal a⁄nity chromatography (IMAC) [8] and tested for their
activity against human heart myosin by ELISA. The recombi-
nant single chain variable fragments (scFv) expressed by E. coli
showed myosin-binding capacity.
From a fundamental point of view, an interesting question
was raised concerning the relationship of this monospeci¢c
mAb with the pathology of the patient from where the B cells
were obtained. This patient possessed an inherited disorder of
platelet function linked to the absence of the integrin KIIbL3
[9]. One explanation for the emergence of this anti-myosin
antibody could be that antigen-driven in vivo selection had
occurred following the increased destruction of platelets dur-
ing the bleeding episodes experienced by the patient and
which resulted in an exposure of the myosin contained in
the platelet cytosol. In such a response to an antigenic stim-
ulus, positive selection of B cells operates within the B cell
repertoire. The B cells therefore became part of the post-acti-
vated repertoire with a high replacement/silent mutation ratio
within the V CDRs [10,11]. The other possibility is that we
have immortalized an autoreactive natural B cell from the
primary repertoire. These naive B cells mostly express unmu-
tated V region genes [12]. Analyses of B7 V gene sequences
establish that the mAb is encoded by virtually unmutated
segments. Therefore, B7 is the product of a naturally occur-
ring antibody-producing B cell from the primary repertoire
with no relation with the bleeding syndrome.
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2. Materials and methods
2.1. E. coli strains, primers and vector
E. coli strain XL1-Blue (Stratagene, La Jolla, CA, USA) was used
as the cloning host. For cloning and sequencing hybridoma-derived V
regions, we used the vector pHOG21 provided by Dr. Melvin Little
(Recombinant Antibody Research Group (0445), German Cancer Re-
search Center, Heidelberg, Germany).
For ampli¢cation of variable domains of Ig W and V chains, we used
5P primers speci¢c for each of the VH and VV gene families and 3P
primers speci¢c for the antisense sequences of CW1 and CV constant
domains [13]. These primers were kind gifts from Dr. Diane Nugent
(Pediatric Hematology Department, CHOC, Orange, CA, USA). We
then used a second set of sense and antisense primers speci¢c for
variable regions, including the restriction sites appropriate for cloning
in the vector pHOG21 [14].
2.2. Isolation and characterization of the human anti-myosin
autoantibody
The human mAb B7 was obtained by EBV transformation followed
by somatic cell hybridization of lymphocytes from a patient with a
bleeding disorder, Glanzmann thrombasthenia [9]. The mAb B7 was
extensively characterized by Western blotting, ELISA and immuno-
histochemistry [3].
2.3. Antigen-binding assay of the parental B7 mAb
B7 mAb was tested at 5 Wg/ml for its binding to ssDNA and
dsDNA by ELISA using the INOVA QUANTA Lite ssDNA and
dsDNA kits (INOVA Diagnostics Inc, San Diego, CA, USA) accord-
ing to the manufacturer’s instructions. B7 was also tested for its bind-
ing to human cardiac myosin (Valbiotech, Paris, France), actin, elas-
tin, keratin, light meromyosin (LMM), heavy meromyosin (HMM)
(Sigma Chemical Co., St Louis, MO, USA), and IgGFc (RF, rheu-
matoid factor) (Jackson ImmunoResearch, West Grove, PA, USA).
Supernatant from a polyspeci¢c cell line obtained by EBV transfor-
mation which secretes an IgM antibody (unpublished data) was in-
cluded in the test at 5 Wg/ml as a positive control for all autoantigens
tested. The ELISA was performed according to Clofent-Sanchez et al.
[15]. Nunc 96-well microtiter plates were coated with 3 Wg/ml of each
antigen. Bound B7 and polyspeci¢c IgM antibody were revealed using
alkaline phosphatase-labeled goat antibodies to human IgM (Fc5W
fragment speci¢c) (Jackson ImmunoResearch).
2.4. Isolation of variable heavy and light chain genes
Total RNA was extracted from about 5U107 hybridoma cells of
¢ve subclones of B7 using TRIzol LS Reagent, a solution of phenol
and guanidine isothiocyanate (Gibco BRL, Eragny Pontoise, France),
according to standard methodology.
Five separated ¢rst-strand cDNA preparations were synthesized
using a constant heavy chain W antisense primer (CW1 gene 3P primer)
or a constant V antisense primer (CV gene 3P primer), the Moloney
Murine Leukemia Virus reverse transcriptase (BRL/Life Technolo-
gies) and RNA guard (Pharmacia Biotech, Saclay, Orsay, France).
The initial cDNA strand was ampli¢ed using primers speci¢c for
each human heavy and light gene families as provided by Dr. D.
Nugent [13]. For the ampli¢cation of the V genes, we combined
each of the six VH family framework region FR1 sense primers and
the antisense primer in separate reactions. For the ampli¢cation of the
VV region genes, we combined six VV family framework region (FR1)
sense primers with the antisense primer. PCR ampli¢cation was car-
ried out in a total of 100 Wl containing 5^50 ng cDNA, 25 pM of each
primer, 300 WM dNTPs, 10 Wl of 10Uampli¢cation bu¡er (100 mM
Tris-HCl, pH 8.8, 15 mM MgCl2, 500 mM KCl, 1% Triton X-100)
and 5 U HITAQ DNA polymerase (Bioprobe Systems, Montreuil
sous Bois, France); 12 separate reactions were performed. Each mix-
ture was subjected to 30 cycles consisting of 94‡C (1 min), 50‡C
(1 min), 72‡C (1 min) using a Gene Amp PCR System 9600 (Per-
kin-Elmer, Foster City, CA, USA). At the end of the last cycle, the
mixture was incubated at 72‡C for 5 min. Ampli¢ed DNA was ana-
lyzed by electrophoresis on a 1.2% agarose gel stained with ethidium
bromide. Speci¢c ampli¢ed fragments of the expected base pair size
(630 bp for the light chain, 680 bp for the heavy chain) were puri¢ed
from the agarose gel and subsequently used for cloning.
2.5. Cloning of hybridoma genes
For Ig heavy and light chain cloning, we used the pHOG21 vector
and a second set of sense and antisense primers containing the suitable
restriction sites [14]. Cycles (30) were 95‡C for 30 s, 55‡C for 1 min,
72‡C for 1 min, followed by 5 min at 75‡C to allow the ¢nal exten-
sion. Speci¢c fragment ampli¢cation of the expected base pair size
(400 bp) was con¢rmed by 1.2% agarose gel electrophoresis on a
10 Wl sample of the ¢nal PCR product. For light chain cloning into
the vector pHOG21, VV DNA was digested with MluI and NotI (re-
striction enzymes obtained from Boehringer Mannheim, Meylan,
France), separated on an agarose gel and puri¢ed. These DNA prod-
ucts were then ligated to MluI/NotI digested pHOG21. The ligation
product was puri¢ed on Geneclean (BIO 101 Inc., La Jolla, CA,
USA). Transformed E. coli XL1-Blue cells (Stratagene, La Jolla,
CA, USA) were grown on LB agar plates containing 100 Wg/ml am-
picillin and 100 mM glucose (LBGA). Clones were tested for the pres-
ence of correctly assembled VV by PCR screening using oligonucleo-
tides VV (backward) and VV (forward). The DNA from 25 positive
clones (¢ve from each cDNA preparation) was extracted with the
Qiaquick kit (Qiagen, Courtaboeuf, France).
2.6. Sequencing and analysis of hybridoma genes
Double-stranded sequencing of the cloned insert was determined
according to the dideoxy method [16]. Insert-carrying clones were
sequenced on both strands. The sequence reaction was performed
with the sequenase sequencing kit (Amersham, Courtaboeuf, France)
using a DNA sequencer (LI-COR DNA Sequencer 4000, ScienceTec,
Les Ulis, France). Sequence identity was con¢rmed from all 25 sepa-
rate clones. Before inserting the VH DNA into a clone containing the
VV gene, it was puri¢ed on 1.2% agarose, digested with NcoI and
HindIII, puri¢ed again on agarose and ligated to the vector of the
previous construct digested with the same enzymes. The transforma-
tion, the selection, and the sequencing of the clones containing the VH
gene were performed as described for the VV gene.
The Ig V region sequences of the heavy and light chain genes were
submitted to the IMGT [17] and V BASE [18] databases to determine
the germline gene sequences.
2.7. Expression of recombinant single chain antibody fragments
XL1-Blue E. coli bacteria transformed with the pHOG21 vector
containing the B7 scFv fragment were grown overnight in LB medium
(Invitrogen, San Diego, CA, USA) with 50 Wg/ml ampicillin and
100 mM glucose (LBGA) at 37‡C. The overnight culture was diluted
(1/20) and the culture continued in 5 l £asks at 37‡C with shaking at
280 rpm. When the culture reached OD600 = 0.7, bacteria were pelleted
by centrifugation at 1500Ug for 10 min at 20‡C and resuspended in
the same volume of fresh LB medium containing 50 Wg/ml ampicillin
and 0.4 M sucrose. The expression of the scFv was induced by the
addition of 1 mM IPTG. The culture was allowed to grow for 18^20 h
at 37‡C.
2.8. Preparation of periplasmic extract and culture supernatant
containing the soluble scFv
Bacteria pellet and culture supernatant were harvested by centrifu-
gation at 5000Ug for 15 min at 4‡C. To isolate soluble periplasmic
proteins, the pelleted bacteria were resuspended in 5% of the initial
volume of ice-cold 50 mM Tris-HCl, 20% sucrose, 1 mM EDTA, pH
8.0. After a 1 h incubation on ice with occasional stirring, the spher-
oplasts were centrifuged at 30 000Ug for 30 min at 4‡C, yielding a
soluble periplasmic extract in the supernatant and insoluble periplas-
mic material in the pellet. The B7 culture supernatant and the soluble
periplasmic extract were combined, clari¢ed by additional centrifuga-
tion (30 000Ug, 4‡C, 30 min) and passed through a 0.2 Wm 1 l ¢lter
(Nalgene, Poly Labo, Strasbourg, France). The clari¢ed supernatant
was concentrated and dialyzed against 50 mM Tris-HCl, 1 M NaCl,
pH 7.0 using a Prep/Scale-ultra¢ltration system (Millipore, St. Quen-
tin Yvelines, France) incorporating a cartridge with a molecular
weight cut o¡ of 5 kDa.
The concentration of scFv was calculated by determining the total
protein concentration using the Micro BCA Protein Assay Reagent
and the NanoOrange protein quanti¢cation kit (Pierce, Interchim,
Montluc°on, France) and by measuring the percentage of scFv by
gel scanning (Image Station 440 CF, Kodak, Rochester, NY, USA).
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2.9. SDS-PAGE and immunoblot analysis
Analysis of the fractions containing scFv was performed by electro-
phoresis on 12% SDS-polyacrylamide gels under reducing conditions.
The gels were Coomassie blue or silver stained (Silver Stain Kit) (Bio-
Rad, Ivry Sur Seine, France). The proteins were also transferred by
electrophoresis to a nitrocellulose membrane for immunoblotting us-
ing the mAb, 9E10 recognizing the c-myc peptide tag. This mouse
mAb was produced in our laboratory from the CRL-1729 clone pur-
chased from ATCC (Rockville, Canada). Bound antibody was de-
tected using peroxidase-labeled sheep anti-mouse IgG antibody (Jack-
son Immunoresearch) and chemiluminescence ECL Western blotting
detection reagents (Pierce).
2.10. Antigen-binding assay of the produced scFv
Myosin-binding activity of the recombinant scFv from a fraction
enriched by IMAC (immobilized metal a⁄nity chromatography)
(manuscript in preparation) was assayed using the ELISA technique
described above with the mAb, 9E10 as the ¢rst and HRP-conjugated
goat anti-mouse IgG as the second antibody. A volume (100 Wl) of
17% IMAC-enriched recombinant scFv (17 Wg/ml) was incubated in
the presence of 1% of Triton X-100 (Sigma Chemical Co.) on plates
coated with the total myosin, LMM or HMM fragments at 4‡C over-
night. As controls, proteins not recognized by the parental mAb (ac-
tin, elastin, keratin, IgGFc, ssDNA, dsDNA) and BSA from Sigma
Chemical Co. (St. Louis, MO, USA) were coated at 5 Wg/ml. A mono-
speci¢c scFv fragment (kindly provided by Melvin Little) directed
against Fab fragments was included in the test as a negative control.
3. Results
3.1. ELISA
In a previous publication [3], we have described how B7
reacted speci¢cally with the myosin heavy chain after separa-
tion of platelet proteins by SDS-PAGE and with no cross-
reactivity with other platelet proteins. In order to con¢rm
the monospeci¢city of this mAb, we have now veri¢ed that
B7 did not react with autoantigens such as ssDNA, dsDNA,
actin, elastin, keratin and RF. As shown in Table 1, OD
values below 0.05 were obtained with all these autoantigens,
whereas the polyspeci¢c IgM gave positive values with an OD
above 1.6. The only positive value for B7 was obtained with
myosin. We further determined that the epitope recognized by
B7 is located on the LMM (light meromyosin: the C-terminal
half of the rod) [19]. All of these results showed that we had
immortalized, by EBV transformation, a B cell which secreted
a monospeci¢c IgM anti-myosin autoantibody.
3.2. Ampli¢cation and identi¢cation of IgW and V chain cDNA
from B7
Ig mRNA was speci¢cally converted to cDNA using either
CW1 or CV speci¢c primers and reverse transcriptase. Heavy
chain cDNA was separately ampli¢ed using primers corre-
sponding to all six VH gene families. Similarly, light chain
cDNA was separately ampli¢ed using primers corresponding
to all six VV gene families. Using the VH3 speci¢c 5P primer, a
single intense DNA band of approximately 680 bp was ob-
tained from B7 mRNA. No DNA bands of the size antici-
pated for a Fd segment (VH+D+JH+CW1) were produced us-
ing any of the ¢ve other VH primers. Using the VV3 speci¢c 5P
primer, a DNA fragment of about 630 bp, corresponding to
the complete V light chain was ampli¢ed from B7 mRNA
(data not illustrated). No DNA was ampli¢ed from B7
mRNA when 5P primers corresponding to the remaining ¢ve
sequences were employed.
3.3. Molecular analysis of the heavy and light chain genes from
the B7 cell line
After cloning, we sequenced the Ig V region genes of the
mAb B7. The nucleotide sequences of the B7 VH3 and VV3
genes termed HAb B7-H3 and HAb B7-L3 are shown in Fig.
1A and B respectively. In order to address the question as to
whether B7 cDNA could be related to a germline sequence
and had accumulated somatic mutations, a computer search
for sequence identity was undertaken against the Ig germline
sequences contained in the V BASE and IMGT database.
Sequence analysis of the B7 VH and VL genes revealed that
the nucleotide sequences HAb B7-H3 and HAb B7-L3 were
most homologous to the p1 germline VH3 [20] and the DPL23
germline VV3 genes [21] respectively.
The nucleotide sequence HAb B7-H3 di¡ers from that of
the germline p1 by two nucleotides (99.3% nucleic acid ho-
mology (292/294) and 98.9% amino acid homology (97/98))
(Fig. 1A). The nucleotide sequence HAb B7-H3 has one silent
mutation (codon 63) and one replacement (a valine substi-
tuted for a leucine at the 81 codon) compared to the germline
p1. The HAb B7-H3 heavy chain employs DN1 (D6-13) and
JH5b genes; the D region deviates from a DN1 sequence by
one replacement (a glycine substituted for an alanine at the
¢rst codon of DN1) [22]. The JH region is identical to the
germline JH5b [23].
The nucleotide sequence HAb B7-L3 was 100% (282/282)
homologous with the DPL23 germline gene [21] and was re-
arranged with a JV2 gene [24]. The JV2 of the HAb B7-L3
di¡ered from the JV2 germline at the ¢rst codon (a valine
substituted for an alanine) (Fig. 1B).
3.4. Expression of the scFv fragments
The anti-myosin scFv fragments were analyzed both from
the periplasmic fraction and supernatant of IPTG-induced
E. coli XL1-Blue transfected with the scFv recombinant
pHOG21 plasmid. After induction, a scFv band with a mo-
lecular weight of 35 kDa was found on SDS-PAGE for the
combined periplasmic and supernatant fraction (Fig. 2A, lane
b) and con¢rmed on immunoblots using the mAb 9E10 (Fig.
Table 1
Monospeci¢city of the human mAb B7
Autoantigens
Myosin HMM LMM Actin Elastin Keratin RF ssDNA dsDNA
B7a 1.5 0.03 0.95 0.04 0.01 0.01 0.05 0.02 0.01
Polyspeci¢c IgMa 1.8 n.d.b n.d. 1.9 1.8 2 1.9 1.6 1.7
Supernatant from the B7 culture was tested for antibody binding in ELISA against di¡erent autoantigens. A polyspeci¢c IgM is used as a posi-
tive control.
aOptical density readings at 405 nm.
bn.d., not detected.
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Fig. 1. A: Nucleotide sequence and translated amino acid sequence of the B7 Ig heavy chain variable region. The VH sequence of B7 is com-
pared with the most homologous germline gene (p1) in the V BASE and IMGT database. Dotted lines signify coidentity of the two sequences
and base changes inducing amino acid replacement are indicated in capital. The CDRs are highlighted in bold. The B7 VH sequence is avail-
able from the EMBL bank (accession number: AJ224899). B: Nucleotide sequence and translated amino acid sequence of the B7 Ig light chain
variable region. The VL sequence of B7 is compared with the most homologous germline DPL23 segment in the V BASE and IMGT database.
Dotted lines signify coidentity of the two sequences and base changes inducing amino acid replacement are indicated in capital. The CDRs are
highlighted in bold. The B7 VL sequence is available from EMBL bank (accession number: AJ224900).
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2A, lane c: periplasmic fraction; lane d: supernatant). The
concentrated E. coli supernatant combined with the periplas-
mic extract was further passed through a Cu2-charged che-
lating Sepharose column (IMAC, manuscript in preparation).
The concentration of proteins in this IMAC eluted fraction
was calculated with the NanoOrange protein quanti¢cation
kit and found to be 100 Wg/ml. SDS-PAGE analysis of mate-
rial puri¢ed by IMAC showed several major proteins of
Mr = 30 kDa, 35 kDa, and 70 kDa (Fig. 2B, lane a) with
only the 35 kDa band reacting with the anti-c-myc antibody
on immunoblot analysis (Fig. 2B, lane b). The percentage of
the scFv in the IMAC preparation was estimated by gel scan-
ning to be 17%. We had thus obtained a concentration of 17
Wg/ml of scFv.
3.5. Biological activity of B7-derived scFv fragments to myosin
The immunoreactivity of the IMAC-enriched B7 scFv prep-
aration was analyzed for its ability to bind to puri¢ed human
myosin in an ELISA assay. Fig. 3 demonstrates that the scFv
at 17 Wg/ml reacted most strongly with human myosin and
consistently generated values well above those obtained with a
control preparation of scFv. The level of reactivity on light
meromyosin (LMM) was comparable to that obtained on to-
tal myosin (OD = 0.3; data not shown). The non-ionic deter-
gent Triton X-100 was included in the preparation of scFv
tested in order to avoid the formation of aggregates. Results
for two other antigens (actin and BSA) were shown on Fig. 3
to verify the immunospeci¢city of B7 scFv fragments. They
were also tested for their binding to HMM, elastin, keratin,
ssDNA, dsDNA, and IgGFc (RF, rheumatoid factor) and
gave the same background values as for actin (OD6 0.08;
data not shown). These values were similar to those obtained
with the control scFv preparation.
4. Discussion
The EBV transformation of B lymphocytes from a Glanz-
mann thrombasthenia patient led to the immortalization of a
monoclonal anti-myosin mAb, named B7, which does not
cross-react with total platelet proteins and other self antigens
(see Table 1). We had previously hypothesized that the pro-
duction of an anti-myosin antibody may have resulted from
an immune response to intracellular proteins exposed during
platelet destruction [3]. Somatically mutated IgM+ memory B
cells are known to circulate in peripheral blood [25,26]. Mo-
lecular studies were therefore performed to determine whether
the immortalized B cell was an antigen-selected B cell or a
naturally occurring autoimmune B cell. The nucleotide se-
quences of the heavy and light chain variable domain genes
of the B7 anti-myosin mAb were analyzed for the closest
germline VH/VL gene usage. The presence of somatic muta-
tions in the CDRs and FRs was also evaluated to gain infor-
mation on the cell origin in the B repertoire. Indeed, high
numbers of amino acid replacement (R) mutations in the
VH segment CDRs compared to relatively unchanged FRs is
consistent with the exertion of a positive antigenic pressure to
mutate the structure of the CDRs and to preserve that of the
FRs [11,27].
The alignment of V, D and J segments with known germline
genes showed that B7 mAb was encoded by poorly mutated
genes. Only two mutations with one amino acid substitution
in the FR3 region were detected when we compared the B7
VH sequence with the germline p1 (99.6% identity). The loca-
tions of these point mutations were not characteristic of those
Fig. 2. A: 12% SDS-PAGE analysis of concentrated culture medium
added to periplasmic extract (20 Wl) of E. coli transfected with the
plasmid encoding B7 scFv. Lanes: a, without IPTG; b, induced
with 1 mM IPTG; c, MW (molecular mass markers) on a Coomas-
sie blue stained gel. No scFv were detected in the concentrated cul-
ture medium and periplasmic extract from non-induced bacteria.
Immunoblot analysis of soluble periplasmic content (lane c) and cul-
ture medium (lane d) of E. coli transfected with pHOG21 and in-
duced with 1 mM IPTG. The scFv were detected using the mAb,
9E10, recognizing the C-terminal c-myc epitope. The arrowhead in-
dicates the position of the scFv. B: 12% SDS-PAGE (lane a on a
silver stained gel) and immunoblot using anti-c-myc antibody (lane
b) analyses of 80 Wl scFv (1.36 Wg scFv) enriched by IMAC (immo-
bilized metal a⁄nity chromatography). lane MW, molecular mass
markers.
Fig. 3. Binding of recombinant B7 scFv at 17 Wg/ml to puri¢ed my-
osin of human heart as determined by ELISA. The results showed
signi¢cant myosin speci¢c binding of the recombinant B7 scFv frag-
ments compared to the binding to actin and BSA antigens. A
monospeci¢c scFv fragment directed against Fab fragments was
used as a negative control.
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resulting from an antigen-dependent selection process. More-
over, as two other antibodies reported in databases expressed
a VH gene sequence 100% homologous to that of B7 (data not
shown), the question as to whether these changes actually
represent mutations or are simply allelic polymorphisms of
the p1 germline gene remains to be answered. Such polymor-
phisms have been reported by Olee et al. [20] for hv3005 and
1.9III germline genes. As for the B7 VL segment, it was found
to be 100% homologous with the DPL23 germline gene (VL3r)
[21].
Overall, the sequence analyses of the B7 V region genes are
in line with it being the product of the primary repertoire with
‘anti-self’ speci¢city. A considerable proportion of cells in
normal individuals secrete natural IgM and IgG antibodies
which react with a variety of self antigens and are encoded
by unmutated Ig V genes [28,29]. A large majority of them are
polyspeci¢c antibodies [30]. Here, we have a B cell of the
primary repertoire able to produce a monospeci¢c anti-myo-
sin antibody.
Because of its speci¢city, B7 may have a potential for the in
vivo detection of myocardial cell death. Radiolabeled anti-
myosin antibodies can bind to insoluble myosin after the
loss of myocyte membrane integrity, therefore allowing the
scintigraphic detection of myocardial necrosis [31]. Anti-my-
osin imaging may be helpful as a non-invasive method in
identifying cardiac rejection and its progression in heart trans-
plants [2], suspected myocarditis [5], muscular tumors [32] and
cardiac side-e¡ects of anthracycline treatment [6,33]. More-
over, B7 is of human origin, and human antibodies are known
to reduce or eliminate immune reactions frequently elicited in
patients upon administration of a murine antibody [34].
However, human monoclonal IgM antibodies may not have
an optimal imaging capability due to their large size [35]. It is
generally assumed that due to steric encumbrance, IgM have a
slow tissue penetration rate [36]. The recent development of
genetically engineered scFv, o¡er the potential to alleviate this
problem [7]. We have constructed a gene encoding for the B7
antibody scFv fragment into the pHOG21 vector and the scFv
were shown to be expressed in a soluble form in E. coli.
Nevertheless, our recent results of scFv puri¢cation (manu-
script in preparation) showed that the level of B7 scFv ex-
pression in the periplasmic space combined to culture medium
is around 0.1 mg/l. It is well known that scFv from di¡erent
antibodies can show very di¡erent yields of secretion within E.
coli, as their unique amino acid sequences can a¡ect their
expression [37]. For example, in identical E. coli host/vector
systems, 1^5 mg/l of anti-glycophorin A 1C3 scFv were found
in the culture medium [38] compared to 0.1^0.5 mg/l of anti-
DNP U7.6 scFv and no anti-transferrin receptor OKT9 scFv
[39]. The low yield of B7 scFv production can be improved by
using fermentation protocols as established by Schiweck et al.
[40]. Here, we have proved that the B7-related scFv fragments
have conserved their speci¢city for the myosin of human
heart. However, diagnostic applications of scFv fragments
often require large amounts of protein. Thus, prior to clinical
application, we will compare B7 scFv production in E. coli,
Pichia Pastoris [41] and in the baculovirus-insect cells expres-
sion system [42]. Both eukaryotic expression systems have
been reported to reach yields in the range of several hundred
milligram per liter. By virtue of their unique myosin speci¢city
and human origin, B7 scFv targeting to damaged myocytes
would be a potential important tool in the imaging of myo-
cardial necrosis for a number of myocardial disorders, as a
non-invasive method.
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